• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilars Articles for the Week of January 27

Article

The Center for Biosimilars® recaps the top stories for the week of January 27, 2020.

Hi, I’m Matthew Gavidia for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of January 27, 2020.

Number 5: Health New England, a nonprofit health plan in Massachusetts, says it achieved 93% utilization of biosimilar infliximab by requiring prior authorization of the brand product, Remicade.

Number 4: An industry executive with Boehringer Ingelheim discusses the impact that the international pricing index could have on drug development.

Number 3: Developing trust in a biosimilar and working out a long-range, multipronged marketing strategy is key to a successful launch, industry executives say.

Number 2: Panelists at the Specialty Therapies and Biosimilars Conference review how successive patents can be filed to keep an original product in a position of market dominance.

Number 1: Pfizer says its 3 oncology biosimilar products—bevacizumab, rituximab, and trastuzumab—will have the lowest wholesale acquisition cost among all other oncology biosimilars.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
The Top 5 Biosimilars Articles for the Week of April 8, 2024.
Ha Kung Wong, JD.
Here are the top 5 biosimilar articles for the week of April 1, 2024.
Here are the top 5 biosimilar articles for the week of March 25, 2024.
Related Content
© 2024 MJH Life Sciences

All rights reserved.